A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2011
05/19/2011	WO2011060065A2 Instillation of liposomal formulation of sirna and antisense oligonucleotides
05/19/2011	WO2011059931A2 Nanosuspension of a poorly soluble drug via microfluidization process
05/19/2011	WO2011059909A1 Polysaccharide gel formulation having multi-stage bioactive agent delivery
05/19/2011	WO2011059478A1 Th1/th2 polarizing vaccines
05/19/2011	WO2011059416A1 Prophylactic antioxidant agent for protecting the tissues of an organism from the action of negative ecological factors or the consequences of smoking tobacco
05/19/2011	WO2011059324A2 Composition for topical application, uses thereof, applicator device and kit of parts
05/19/2011	WO2011059075A1 Glutamic acid-rich and arginine-rich preparation
05/19/2011	WO2011059073A1 Phospholipid derivative and ph-responsive liposomes
05/19/2011	WO2011059037A1 Pharmaceutical composition for external use
05/19/2011	WO2011058988A1 Antiviral agent-supporting sheet and method for producing same
05/19/2011	WO2011058881A1 Apparatus for producing ultrafine liquid droplets
05/19/2011	WO2011058764A1 Gargle preparation, and process and apparatus for production of same
05/19/2011	WO2011058449A2 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
05/19/2011	WO2011058443A1 Method and device to induce collagen biomineralisation
05/19/2011	WO2011058366A1 Use of bethanechol for treatment of xerostomia
05/19/2011	WO2011058336A2 Tablet
05/19/2011	WO2011058046A1 Silica particle including a molecule of interest, method for preparing same and uses thereof
05/19/2011	WO2011058018A2 Biocompatible, magnetic nanoparticles for treating glioblastomae
05/19/2011	WO2011057686A1 Oral formulations with high oral bioavailability consisting of mixtures of lipophilic and hydrophilic fractions obtained from propolis
05/19/2011	WO2011057676A1 A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
05/19/2011	WO2011038064A3 Manufacture of tablet in a die utilizing powder blend containing water-containing material
05/19/2011	WO2011034274A3 Pharmaceutical compositions comprising bisphosphonate derivatives and high-dose cholecalciferol
05/19/2011	WO2011027258A3 Scented capsules
05/19/2011	WO2011018582A3 Floating microgranules
05/19/2011	WO2011017502A3 Linaclotide-containing formulations for oral administration
05/19/2011	WO2011011351A3 A stable pharmaceutical omeprazole formulation for oral administration
05/19/2011	WO2011008001A3 Antihypertensive composition containing a ginsenoside-enriched fraction
05/19/2011	WO2011006079A3 Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using
05/19/2011	WO2010151778A3 Topical compositions and methods for wound care
05/19/2011	WO2010151338A3 Myostatin inhibitor enhancement of musculoskeletal repair
05/19/2011	WO2010151080A3 Pharmaceutical composition containing carboxylosartan and a production method therefor
05/19/2011	WO2010151020A3 Fast-dissolving oral film for effectively concealing unpleasant tastes
05/19/2011	WO2010151005A3 Injectable composition containing hydroxychloroquine for local administration for treating cancer
05/19/2011	WO2010151004A3 Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
05/19/2011	WO2010148288A3 Pharmaceutical formulations with low aqueous levels of free unbound drug
05/19/2011	WO2010147387A3 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides as active ingredients
05/19/2011	WO2010140855A3 Pharmaceutical composition or functional food composition for the treatment, prevention or alleviation of cardiac hypertrophy comprising raspberry extract
05/19/2011	WO2010139654A3 Orally disintegrating dosage forms containing taste-masked active ingredients
05/19/2011	WO2010130799A3 Method for impregnation with supercritical co2
05/19/2011	WO2010102252A9 Oral dosage forms having a high loading of a gabapentin prodrug
05/19/2011	WO2009135179A3 The use of solid carrier particles to improve the processability of a pharmaceutical agent
05/19/2011	US20110118825 Anti-angiogenic compositions and methods of use
05/19/2011	US20110118533 Polymer microgel beads and preparative method thereof
05/19/2011	US20110118348 Methods of stabilizing latanoprost in an aqueous solution
05/19/2011	US20110118294 Intranasal Opioid Compositions
05/19/2011	US20110118174 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
05/19/2011	US20110117206 Phosphopeptides and use of the same
05/19/2011	US20110117205 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
05/19/2011	US20110117204 Immunologically active compositions
05/19/2011	US20110117203 Pharmaceutical composition containing water soluble drug
05/19/2011	US20110117202 Up and down conversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion
05/19/2011	US20110117201 Composition for treatment of water
05/19/2011	US20110117200 Rasagiline mesylate particles and process for the preparation thereof
05/19/2011	US20110117199 Foamy biomaterial for biological tissue repair
05/19/2011	US20110117198 Compositions of semi-interpenetrating polymer network
05/19/2011	US20110117197 Sustained-release drug carrier composition
05/19/2011	US20110117196 Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
05/19/2011	US20110117195 Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
05/19/2011	US20110117194 Pharmaceutical formulation containing angiotensin-ii receptor blocker
05/19/2011	US20110117193 Antiretroviral drug formulations for treatment of children exposed to hiv/aids
05/19/2011	US20110117192 Carbidopa/lipodopa gastroretentive drug delivery
05/19/2011	US20110117191 Mixture of substances on the basis of a mixture of essential oils and use
05/19/2011	US20110117190 Pharmaceutical Formulations
05/19/2011	US20110117189 Ophthalmic compositions for treating pathologies of the posterior segment of the eye
05/19/2011	US20110117188 Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof
05/19/2011	US20110117187 Topical compositions and methods for epithelial-related conditions
05/19/2011	US20110117186 Intravenous infusion of curcumin and a calcium channel blocker
05/19/2011	US20110117185 Methods for treating or preventing heart damage with integrin-linked kinase (ilk) compositions
05/19/2011	US20110117184 Compositions for mucosal delivery of agents
05/19/2011	US20110117183 Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
05/19/2011	US20110117182 Combination of dapsone with other anti-acne agents
05/19/2011	US20110117181 Treating hepatitis c virus infection with over-expression of microrna-196
05/19/2011	US20110117180 Vegetarian microcapsules
05/19/2011	US20110117179 Compositions comprising elemental metals and uses therefor
05/19/2011	US20110117178 Wound dressing comprising a hydrogel matrix
05/19/2011	US20110117177 Method for producing a multilayer compound on a CIP-capable coating installation and use of the multilayer compound produced by said method for transdermal application or the application in body cavities
05/19/2011	US20110117175 Sweet analgesic for use in medical procedures or treatments
05/19/2011	US20110117174 Adhesive article containing colorant and/or active agent
05/19/2011	US20110117173 Powdered chewing gum compositions, the use thereof and a method of preparing such compositions
05/19/2011	US20110117172 Cross-linked polymer matrix, in particular for administering active substances
05/19/2011	US20110117171 Implantable bone graft materials
05/19/2011	US20110117170 Controlled Release of Growth Factors and Signaling Molecules for Promoting Angiogenesis
05/19/2011	US20110117169 Methods and compositions for capture of cells
05/19/2011	US20110117168 Methods and compositions for soft tissue repair
05/19/2011	US20110117167 Methods and compositions for soft tissue repair
05/19/2011	US20110117164 Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers
05/19/2011	US20110117162 Isolated Renal Cells and Uses Thereof
05/19/2011	US20110117160 Antagonistic properties of reef fish microflora
05/19/2011	US20110117154 Use of rifalazil to treat colonic disorders
05/19/2011	US20110117151 Device,system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
05/19/2011	US20110117150 Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
05/19/2011	US20110117149 Inorganic nanotubes
05/19/2011	US20110117148 Whitened exine shells
05/19/2011	US20110117143 TREATMENT OF CELIAC DISEASE WITH IgA
05/19/2011	US20110117142 Method for coating tablets
05/19/2011	US20110117141 Methods and compositions comprising novel cationic lipids
05/19/2011	US20110117140 Zinc Salt Compositions for the Prevention of Dermal and Mucosal Irritation
05/19/2011	US20110117139 Fully synthetic albumin analog
05/19/2011	US20110117138 Charge-dynamic polymers and delivery of anionic compounds
05/19/2011	US20110117030 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections

1 ... 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 ... 2991